Goal
Intra-amniotic infection increases the risk of obstetric complications and problems in the fetus and newborn, making early and rapid diagnosis of great importance. The objective of this project is to evaluate the clinical performance of the Actim IAI quantitative test that detects intra-amniotic infection through the presence of MMP-8 protein (matrix metalloproteinase-8) in amniotic fluid during pregnancy.
Start: 2019; End: 2021
“We collaborate with industry to validate a rapid, in-situ quantitative test for the detection of intra-amniotic infections during pregnancy.”
Innovation & Impact
Intra-amniotic infections remain a significant public health problem. With a prevalence of approximately 20% in women with threatened preterm delivery and 37-40% in women with premature rupture of the membranes, they are an important cause of infectious and neonatal maternal morbidity, mainly due to their relationship with premature delivery. Collaborating on this project, we contribute to the validation of rapid and effective tests that can help detect intra-amniotic infections at the patient’s bedside and thus reduce their negative impact on maternal and fetal health.
Outcomes
Publications
Deliverables
Financers
Helsinki, Finlandia
Powered by
With the collaboration of
